蝮蛇抗栓酶治疗高粘滞血症23例甲襞微循环的观察（摘要）

蝮蛇抗栓酶治疗高粘滞血症２３例甲襞微循环的观察（摘要）南京市钟山医院张思效本文对２３例高粘滞血症患者在用蝮蛇抗栓酶治疗前后以甲襞微循环进行对比观察,证明治疗后甲襞微循环状态有显著改善。从加权积分值变化可以看出;管袢形态Ｐ＜０．００５,管袢流态Ｐ＜０．...     

清栓酶对过氧化脂质含量影响的研究

将５４例冠心病、高血压病、糖尿病及脑梗塞病人,随机分为对照组与清栓酶组。对照组２６例,常规药物治疗,清栓酶组２８例,在常规药物治疗基础上加用蝮蛇清栓酶０．５ｕ,稀释静脉点滴,一日一次,１４天为一疗程。观察到蝮蛇清栓酶能明显升高超氧化物岐化酶活性（Ｐ＜０．０１）,明显降低过氧化脂质的终末代谢产物丙二醛含量（Ｐ＜０．０１）,说明蝮蛇清栓酶能有效减轻自由基损伤。     

清栓酶治疗脑血管疾病的甲襞微循环监测报告

清栓酶治疗脑血管疾病的甲襞微循环监测报告贵阳市花溪区人民医院血栓科赵丽萍我院于１９９０年至１９９２年对３００例脑血管疾病应用清栓酶（治疗组）,另以２００例应用７０６代血浆加丹参液（对照组）,进行甲襞微循环观察比较。报告如下：观察对象和方法一、观察对象...     

蝮蛇抗栓酶治疗高脂血症及心电图分析

应用蝮蛇抗栓酶治疗高脂血症３８例,１个月后观察血脂下降、血液流变学改善（Ｐ＜０．０５）、心电图改善,总有效率７５％,尤其是对ＳＴ—Ｔ异常、早博的疗效较好。     

东菱克栓酶加低分子肝素治疗急性脑梗死的疗效及安全性研究

目的 观察东菱克栓酶加低分子肝素治疗急性脑梗死的疗效及安全性。方法 在东菱克栓酶常规疗程结构后。２８例人造病人加用低分子肝素皮下注射。结果 总有效率达８２．１４％,神经功能缺损评分显著进步（Ｐ〈０．０５）。血液流变学多项指标进一步改善;而且加用低分子肝素后ＰＣＴ、ＰＴ、ＫＰＴＴ的影响不大（Ｐ〉０．０５）。结论 严格人造标准和必要的凝血功能监测。加用低分子肝素能在一定程度上提高疗诳改善预后,临床出血     

蝮蛇抗栓酶对微循环作用的实验与临床研究

对实验性失血性休克的４０只大鼠和１５只家兔静注不同剂量的抗栓酶,用激光多普勒微循环血流计测定肾表面固定部位的微循环血流量,发现用药后血流量显著增加且与尿量相一致;阻断６０只沙鼠颈动脉造成脑缺血模型,在颅顶开窗用微循环显微镜观察用药后软脑膜微循环的变化,发现微循环血流速度加快并显示一定的冲击力,且能减少白细胞数及贴壁滚动;用２０只家兔做成ＤＩＣ模型,给抗栓酶后观察肠系膜微循环,发现毛细血管开放数增多,微循环流态改善。观察３３例脑血栓形成期病人用抗栓酶治疗前后甲襞微循环的变化,发现治疗后微循环总积分值改善,流态改善更明显     

以经颅多普勒血流仪对蝮蛇抗栓酶与速效溶栓清治疗缺血性脑血管病颅内动脉血流变化的观察

６２例缺血性脑血管病患者,其中４２例为蝮蛇抗栓酶治疗组,２０例为速效溶栓清治疗组。治疗前后分别用经颅多普勒血流仪（ＴＣＤ）检查脑血管（大脑中动脉ＭＣＡ、前动脉ＡＣＡ及后动脉ＰＣＡ）血流平均值Ｖｍ。结果显示,两组患者被治疗后脑血管血流Ｖｍ均明显增高（Ｐ＜０．０５或Ｐ＜０．０１）,但两组间无显著性差异（Ｐ＞０．０５）。表明两种药物治疗缺血性脑血管病疗效相仿,但速效溶栓清价格较高     

锰对作业工人血液流变学的影响及清栓酶的疗效观察

本文对１０３例锰作业工人测定了血液流变学中的七项指标,结果表明：全血粘度（高切、低切）、血浆粘度、红细胞压积、纤维蛋白原、红细胞电泳、血小板粘附、血沉等项指标,均明显高于正常对照组（Ｐ＜０．０１）,证实锰作业工人普遍存在高粘滞血症,为临床治疗锰中毒开辟新的途径提供了依据。对其中的５２例锰中毒（包括症状较重的观察对象）,用清栓酶治疗后,复查其七项指标与治疗前比较,均有明显下降（Ｐ＜０．０１）,其症状与体征得以改善,进一步说明清栓酶是治疗锰中毒的理想药物之一。     

蕲蛇酶对甲襞微循环的影响

蕲蛇酶具有抗凝、降脂、去纤、溶栓、改善微循环的作用,鉴于此,我院于1991年开始使用蕲蛇酶治疗血栓性血管疾病,同时对使用蕲蛇酶进行了甲襞微循环的观测,现将我院使用蕲蛇酶治疗血栓性血管疾病63例患者的甲襞微循环观察如下。1　资料与方法1.1　观察对象　63例患者全部为住院病人,采取随机抽样。血栓闭塞性脉管炎9例,动脉硬化闭塞症12例,糖尿病肢端坏疽7例,静脉血栓形成35例。1.2　临床用药　蕲蛇酶注射液(福建三明制药厂)0.5～0.75u加入生理盐水250ml中静脉点滴(需做药敏试验,或加入地塞米松5mg),每天1次,7天为1个疗程,一般用1～2个疗程,…     

抗栓剂与葡萄糖经紫外线氧透照治疗缺血性脑血管病探讨〔附70例分组疗效对比分析〕

本研究以清栓酶、川芎嗪为抗栓剂加入葡萄糖中,经紫外线氧透照仪照射后输入静脉,治疗缺血性脑血管病,并与单用抗栓剂组作对照,进行疗效对比,结果发现抗栓剂加紫外线氧透照组的显效率显著高于对照组（Ｐ＜０．０５）。说明经紫外线氧透照后的葡萄糖作为载体,有分解出氧原子以提高血氧含量改善脑组织的缺氧状态,并有激活清栓酶和川芎嗪的效应。     

Study of HIV-1 Drug Resistance in Patients Receiving Free Antiretroviral Therapy in China

To investigate the prevalence of drug-resistance mutations,resistance to antiretroviral drugs,and the subsequent virological response to therapy in treatment-naive and antiretroviral-treated patients infected with HIV/AIDS in Henan,China,a total of 431 plasma samples were collected in Queshan county between 2003 and 2004,from patients undergoing the antiretroviral regimen Zidovudine Didanosine Nevirapine(Azt Ddi Nvp).Personal information was collected by face to face interview.Viral load and genotypic drug resistance were tested.Drug resistance mutation data were obtained by analyzing patient-derived sequences through the HIVdb Program(http://hivdb.stanford.edu).Overall,38.5% of treatment-naive patients had undetectable plasma viral load(VL),the rate significantly increased to 61.9% in 0 to 6 months treatment patients(mean 3 months)(P<0.005)but again significantly decrease to 38.6% in 6 to 12 months treatment patients(mean 9 months)(P<0.001)and 40.0% in patients receiving more than 12 months treatment(mean 16 months)(P<0.005).The prevalence of drug resistance in patients who had a detectable VL and available sequences were 7.0%,48.6%,70.8%,72.3% in treatment-na?ve,0 to 6 months treatment,6 to 12 months treatment,and treatment for greater than 12 months patients,respectively.No mutation associated with resistance to Protease inhibitor(PI)was detected in this study.Nucleoside RT inhibitor(NRTI)mutations always emerged after non-nucleoside RT inhibitor(NNRTI)mutations,and were only found in patients treated for more than 6 months,with a frequency less than 5%,with the exception of mutation T215Y(12.8%,6/47)which occurred in patients treated for more than 12 months.NNRTI mutations emerged quickly after therapy begun,and increased significantly in patients treated for more than 6 months(P<0.005),and the most frequent mutations were K103N,V106A,Y181C,G190A.There had been optimal viral suppression in patients undergoing treatment for less than 6 months in Queshan,Henan.The drug resistance strains were highly prevalent in antiretroviral-treated patients,and increased with the continuation of therapy,with many patients encountering virological failure after 6 months therapy.     

中西医结合治疗下肢血栓性静脉炎90例疗效观察

目的观察中西医结合治疗下肢血栓性静脉炎的临床效果。方法将2012年1月~2014年12月我院收治的下肢血栓性静脉炎患者90例采用随机分组法分为治疗组和对照组各45例,对照组给予单纯西医治疗,治疗组给予中西医结合治疗,观察比较两组治疗效果,并分析两组治疗前后C反应蛋白(CRP)、纤维蛋白原(Fbg)的变化情况。结果治疗组总有效率为97.78%,对照组为71.11%,两组比较差异有显著统计学意义(P0.05)。治疗后,治疗组CRP、Fbg与治疗前比较,差异具有显著统计学意义(P0.001或P0.05);而对照组CRP与治疗前比较无显著性差异(P0.05),Fbg与治疗前比较差异有统计学意义(P0.05)。结论中西医结合治疗下肢血栓性静脉炎的临床效果显著。     

微波热凝治疗变应性鼻炎的临床应用研究及治疗机制探讨

目的:研究微波热凝治疗变应性鼻炎的临床意义。方法:将6 3例变应性鼻炎随机分为两组,观察组31例施以微波凝固筛前神经鼻外侧支治疗,对照组32例施以抗组胺药物治疗。结果:两组近期和远期有效率分别是93.5 %、81.5 %和5 3.1%、4 5 .4 %。两组间疗效有显著差异(p <0 .0 1)。结论:微波热凝治疗变应性鼻炎是一种安全有效经济实用的方法,具有临床使用价值。     

激光佐治慢性皮肤溃疡疗效观察及诱导HSP70表达研究

目的:探讨激光治疗慢性皮肤溃疡的疗效及诱导创面组织热休克蛋白70(heat shock prote in 70,HSP70)表达情况。方法:将64例84处慢性皮肤溃疡创面随机分为传统治疗组和激光治疗组,激光治疗组在传统治疗基础上加用激光治疗,所有创面在治疗三周进行疗效判定;同期随机切取5例创面组织,并设正常皮肤为对照,行组织切片HSP70免疫组化染色,计数HSP70阳性细胞数并检测阳性细胞灰度值进行统计学分析;设计引物行RT-PCR检测HSP70mRNA表达情况。结果:两组慢性皮肤溃疡患者经相应治疗均较治疗前明显改善,但激光治疗组创面的治愈率和总有效率明显高于传统治疗组(P<0.05或P<0.01);免疫组化染色显示,正常皮肤和慢性溃疡组织中未见明显HSP70阳性表达细胞,激光治疗后三周后可见较多量的HSP70表达阳性细胞,其阳性细胞计数明显高于其它两组(P<0.01),细胞信号灰度表达明显低于其它两组(P<0.05),而传统治疗组与正常对照组无显著差异;RT-PCR结果发现激光治疗组组织中扩增到一条特异性泳带,大小约268 bp,正常皮肤和传统治疗组组织中未扩增到明显HSP70mRNA基因片段。结论:激光佐治慢性皮肤溃疡具有良好临床疗效,可能与激活创面细胞的热休克内源性保护机制而发挥抗感染和促进愈合作用有关。     

Pharmacogenomics and systems biology of membrane transporters

Membrane transporters are essential for fundamental cellular functions and normal physiological processes. These molecules influence drug absorption and distribution, and play key roles in drug therapeutic effects. A primary goal of current research in drug discovery and development is to fully understand the interaction between transporters and drugs at both system level and individual level for personalized therapy. Pharmacogenomics studies the genetic basis of the individual variations in response to drug therapy, whereas systems biology provides the understanding of biological processes at the system level. The integration of pharmacogenomics with systems biology in membrane transporter study is necessary to solve complex problems in diseases and drug effects. Such integration provides insight to key issues of pharmacogenomics and systems biology of membrane transporters. These key issues include the correlations between structure and function, genotype and phenotype, and systematic interactions between different transporters, between transporters and other proteins, and between transporters and drugs. The exploration in these key issues may ultimately contribute to the personalized medicine with high efficacy but less toxicity, which is the overall goal of pharmacogenomics and systems biology.     

Chemotherapy of vascularised tumours: Role of vessel density and the effect of vascular “pruning”

In this work we propose to model chemotherapy taking into account the mutual interaction between tumour growth and the development of tumour vasculature. By adopting a simple model for this interaction, and assuming that the efficacy of a drug can be modulated by the vessel density, we study the constant continuous therapy, the periodic bolus-based therapy, and combined therapy in which a chemotherapic drug is associated with an anti-angiogenic agent. The model allows to represent the vessel-disrupting activity of some standard chemotherapic drugs, and shows, in the case of constant continuous drug administration, the possibility of multiple stable equilibria. The multistability suggests an explanation for some sudden losses of control observed during therapy, and for the beneficial effect of vascular “pruning” exerted by anti-angiogenic agents in combined therapy. Moreover, in case of periodic therapies in which the drug amount administered per unit time is constant (“metronomic” delivery), the model predicts a response, as a function of the bolus frequency, significantly influenced by the extent of the anti-angiogenic activity of the chemotherapic drug and by the dependence of the drug efficacy on the vessel density.     

思连康治疗溃疡性结肠炎的疗效及机制研究

目的研究微生态制剂思连康辅助治疗溃疡性结肠炎的疗效及其可能的机制。方法将溃疡性结肠炎患者79例随机分成治疗组及对照组,治疗组40例,对照组39例。对照组采用常规治疗,治疗组在常规治疗的基础上加用双歧四联活菌制剂——思连康。比较2组治疗前及治疗2个月后患者的临床症状评分、结肠黏膜炎症表现、细胞因子IL-10、IL-18的变化。结果治疗2个月后2组临床症状评分、结肠黏膜炎症评分均较治疗前有明显改善（P〈0.01）,且治疗组临床症状、结肠黏膜炎症改善程度优于对照组（P〈0.01）,IL-10、IL-18的含量治疗前后有明显的变化,IL-10增加,IL-18降低。结论思连康可辅助治疗溃疡性结肠炎,其机制可能是通过调节细胞因子的变化,进一步影响结肠黏膜的免疫功能。     

丽珠肠乐治疗溃疡性结肠炎的临床疗效及病理变化的研究

目的:探讨溃疡性结肠炎的微生态学改变及双歧杆菌对溃疡性结肠炎的预防和治疗作用.方法:随机选取溃疡性结肠炎的患者60人,分成二组.治疗组:口服丽珠肠乐胶囊;对照组:口服氟哌酸胶囊,柳氮磺胺吡啶栓直肠给药.疗程一个月.结果:溃疡性结肠炎的肠道内细菌数量双歧杆菌、乳杆菌显著下降(P＜0.01),肠球菌显著增加(P＜0.01).经丽珠肠乐治疗后,肠道内主要细菌的数量恢复正常,与对照组相比差异有显著性(P＜0.01);肠道黏膜病理及组织学改变基本恢复正常;临床症状改善上治疗组疗效高于对照组(P＜0.01).结论:双歧杆菌活菌制剂治疗溃疡性结肠炎效果显著,值得临床推广使用.     

生物Fas和Bcl-2在胸腺瘤患者瘤组织表达中与并发重症肌无力的相关性研究

探讨胸腺瘤患者瘤组织中凋亡诱导基因Fas和凋亡抑制基因Bcl-2的表达情况及其与胸腺瘤患者并发重症肌无力（MG）的相关性。通过免疫组化S-P法,检测经手术治疗的胸腺瘤伴MG患者切除瘤组织中Fas、Bcl-2的表达水平,并以胸腺瘤不伴MG患者瘤组织中Fas、Bcl-2的表达水平作为对照。Fas在伴有MG的胸腺瘤中的表达高于对照组,差别有显著性意义（P〈0.01）;Bcl-2在伴有MG的胸腺瘤中的表达低于对照组,差别有显著性意义（P〈0.01）。胸腺瘤合并MG患者瘤组织中凋亡诱导基因Fas呈高表达和凋亡抑制基因Bcl-2呈低表达与胸腺瘤患者并发MG有相关性。     

枸杞提取液对实验性肾动脉狭窄性高血压损伤鼠的治疗

目的:探讨枸杞提取液对高血压疾病的治疗作用和可能的机制.方法:将30只健康SD大鼠随机分为正常组,对照组和治疗组,每组10只.对照组和治疗组建立肾动脉狭窄性高血压模型,治疗组每日给予枸杞提取液灌胃处理,对照组给予生理盐水灌胃处理.饲养一个月后,取SD大鼠心脏、肾脏、大脑做组织病理学方面的检测.结果:与对照组相比较,治疗组血压明显下降(P＜0.05),血浆NO合酶cGMP含量明显上升(P＜0.05),心肌细胞横截面积有统计性差异(P＜0.05);心肌组织结构接近正常,且脑血管病理改变轻.对照组的肾、心、脑组织内cGMP水平与正常组相比显著升高,治疗组cGMP水平较对照组降低,且差别有统计学意义.与对照组和正常组相比,治疗组大鼠心、肾凋亡阳性细胞计数差异均有统计学意义(P＜0.05).凋亡因子Bcl-2水平在脑组织内表达显示了组间的差异显著.结论:枸杞提取液对肾源性高血压造成的脏器损害具有保护作用,能够预防由于氧自由基造成的损伤,其作用机制与调节血管活性物质水平和抗氧自由基损伤有关.